Why Your Supplement Stack Should Change Over Time
A stack is a snapshot of a moving system. The specific mechanisms by which a correct protocol becomes a stale one, and how to notice before it matters.
The Short Answer
A supplement protocol is a solution to a problem as it existed on the day it was built, and both halves of that sentence expire. The person changes with age, season, location, training load, body composition, medication, sleep pattern and menopausal status. The evidence changes as trials publish, interaction data accumulates and regulatory positions shift by jurisdiction. Because the ten biological systems are coupled, a change in one propagates into others, which means the constraint a protocol was built to address may have moved to a different Pillar entirely. Nothing about the protocol itself will indicate that this has happened.
The Two Sources of Drift
Protocols become stale from two directions at once, and they are worth separating because the detection methods differ.
Person drift. The individual changes while the protocol stays fixed. This includes slow changes such as ageing and body composition, cyclical changes such as season and training periodisation, and discrete events such as a new medication or a relocation.
Evidence drift. The knowledge base changes while the protocol stays fixed. A compound gains or loses trial support, an interaction is characterised, a regulator changes its position, or a quality issue emerges with a product category.
Person drift is at least in principle noticeable by the person. Evidence drift is not: it requires someone to be tracking a literature that publishes faster than any individual can read, and it is the reason a three-year-old stack can be wrong in ways its owner has no way of detecting.
Person Drift: The Specific Mechanisms
- Season and latitude. Vitamin D requirement changes across the year, and a dose set in late summer is frequently inadequate by late winter. Relocation changes it within weeks.
- Training load. A change in volume or intensity changes protein requirements, creatine relevance, sweat magnesium losses, and the antioxidant timing question, since high-dose antioxidants around training blunt adaptation.
- Medication. The most consequential item. A new prescription can turn an established supplement into an interaction problem overnight, and cytochrome P450 inhibition by compounds such as berberine, quercetin, resveratrol and fisetin affects a large share of prescribed drugs.
- Body composition. Affects vitamin D dose requirements, hormonal profile through aromatase activity, and metabolic markers.
- Age. Protein requirements per meal rise with reduced anabolic sensitivity. Absorption capacity changes, which shifts the ubiquinol versus ubiquinone calculation. B12 absorption declines.
- Menopausal status. Changes bone, cardiovascular, sleep and thermoregulatory context substantially.
- Resolved objectives. A corrected vitamin D concentration calls for a maintenance dose rather than a repletion dose. An addressed inflammatory source may make an anti-inflammatory addition redundant.
- New findings. A laboratory result or clinical finding can reframe the whole protocol and move parts of it into clinical territory.
Evidence Drift: Why It Is Invisible
Three concrete examples of how the evidence base has moved under standing protocols in recent years.
Nicotinamide riboside and muscle. Early enthusiasm was based on blood NAD+ elevation. Subsequent trials measuring muscle NAD+ directly found no increase in healthy older adults despite large blood increases, along with null functional endpoints. Anyone whose protocol was justified by the earlier framing is holding a justification the literature has weakened.
Ashwagandha and liver signals. A series of case reports describing cholestatic liver injury led several regulators to restrict sale or require warnings. A person who added it years ago on the basis of stress trials would have no reason to revisit it unless someone was tracking that development.
Antioxidants and training adaptation. The finding that high-dose vitamin C and E, and in one trial resveratrol, blunt training adaptations reversed the reasoning for a common practice. The compound did not change; the correct timing did.
Regulatory drift is a fourth, quieter category. NMN's status in the United States, ashwagandha restrictions in specific European markets, and varying novel food positions on other compounds mean that the same protocol is compliant in one jurisdiction and not in another, and that a member who relocates may find their stack has changed status without changing content.
The Coupled-System Problem
The deepest reason protocols go stale is that the biological systems are not independent.
A member who fixes their sleep changes their inflammatory markers, their glycaemic handling and their hormonal profile. That may resolve the objective behind two compounds in their stack and reveal a different limiting constraint. The protocol was correct for the previous state of the system and is now addressing a problem that has moved.
This is why "add and keep" is the wrong model. In a coupled system with feedback loops, there is no stable optimum, only states that persist while their inputs persist. The useful question at any review is not "what else should I add" but "where is the constraint now", and the answer changes.
How Stacks Actually Fail
Observed failure modes, in rough order of frequency.
Accretion. A compound is added for a reason, the reason lapses, and the compound stays. After a few years a person is taking several things whose original justification they cannot state, at a cumulative cost and interaction surface nobody has reviewed.
Dose escalation in place of removal. A compound produces no perceptible effect, so the dose is raised rather than the compound removed. This is particularly common for compounds whose effects are not perceptible at all, where no dose would produce a sensation.
Stale dose after context change. The vitamin D dose that was right in February, still being taken in July. The magnesium dose set before a move to a hot climate and heavy training.
Undetected interaction. A new prescription introduced without a stack review, which is the failure mode with the highest consequence.
Redundancy. Multiple products filling one functional slot, or working against each other, as with nicotinamide from a B-complex alongside an NAD+ precursor.
Objective amnesia. Nobody wrote down what the compound was for or what would count as evidence to stop, so no review can reach a conclusion.
What a Well-Governed Protocol Looks Like
Not a fixed list, but a maintained one, with four properties.
Every item has a recorded objective, observation window and stopping condition. Without these, review is impossible and continuation is automatic.
A scheduled review at a biologically sensible interval. Quarterly matches the timescales of HbA1c, vitamin D plateau, membrane fatty acid turnover and most trial durations.
Explicit triggers outside the schedule. New medication, new clinical finding, illness or planned procedure, relocation or major season change, substantial change in training load or work pattern.
One change per cycle. Several simultaneous changes make attribution impossible and turn the protocol into an accumulation of unfalsifiable decisions.
The uncomfortable implication is that maintaining a protocol requires more attention than building one, and that the attention is the part that produces the result. A stack is easy. Keeping it aligned with a changing person and a moving evidence base is the actual work.
The AEONNN Perspective
This is the observation AEONNN was built around. Continuity is the product, not the recommendation, because a recommendation is correct as of a date and a person continues past that date.
Two of the drift mechanisms are effectively undetectable by an individual. Evidence drift requires continuous tracking of a literature that publishes faster than anyone can read, which is what the Database Matrix layers exist for, including the Innovation layer for emerging signals and the Regulatory layer for jurisdictional change. And the coupled-system problem requires reasoning across all ten Pillars simultaneously to notice that a constraint has moved, which is what the Pillar Matrix exists for.
AEONNN Shield is the architecture being built specifically for this: to hold the alignment between a member's biology, their behaviour and time, and to notice when that alignment has degraded. Contingency handles the cyclical and situational cases, travel and stress at launch, where a protocol needs to adapt for a period rather than permanently. Neither is a feature bolted onto a recommendation engine. They are the reason the recommendation engine is worth having.
Pillar Matrix mapping
Longevity and Biological Age, Metabolic and Cardiovascular Health, Sleep and Circadian Regulation
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Safety Layer (DrugBank, FAERS)
- Real-Time User Layer (wearable and adherence signals)
- Regulatory Layer (EFSA, FDA, EMA)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
Frequently Asked
How often should a supplement stack be reviewed?
Quarterly as a default, because that matches the biological timescales of HbA1c, vitamin D plateau, membrane fatty acid turnover and most trial durations. Plus specific triggers: new medication, new clinical finding, illness or procedure, relocation or season change, and a substantial change in training load.
What is the most dangerous kind of protocol drift?
An undetected interaction after a new prescription. Several common supplements inhibit cytochrome P450 enzymes that metabolise a large share of prescribed drugs, and the change happens overnight without any perceptible signal.
Why can I not detect evidence drift myself?
Because it requires continuous tracking of a literature that publishes faster than any individual can read, plus regulatory positions that vary by jurisdiction. A three-year-old stack can be wrong in ways its owner has no way of noticing.
Should supplements be cycled?
Cycling for its own sake is folklore for most compounds. Defined-period use with a review point is different and defensible, particularly where long-term data are absent or a safety signal exists, as with ashwagandha.
What happens if I just keep taking the same stack?
The most common outcome is accretion: items whose original justification has lapsed, a stale dose after a context change, redundancy across products, and an unreviewed interaction surface. None of these produce a noticeable signal.
Why does fixing one thing change the rest of the protocol?
Because the biological systems are coupled. Improving sleep changes inflammatory markers, glycaemic handling and hormonal profile, which can resolve the objective behind existing compounds and move the limiting constraint to a different system.
Is it better to add or remove?
Removal is usually the higher-value action at review. Anything whose objective cannot be stated, that failed a fair test, whose objective has been resolved, or that duplicates another item in the same functional slot should come out.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.